**Question:** Drugs or biological products for diagnosis, treatment or prevention of a rare disease or condition are called-

A. Orphan drugs
B. Unique drugs
C. Niche drugs
D. Exclusive drugs

**Correct Answer:** A. Orphan drugs

**Core Concept:** Orphan drugs refer to medications, biological products, or treatments developed specifically for the diagnosis, treatment, or prevention of rare diseases or conditions. Rare diseases are defined as those affecting fewer than 200,000 individuals in the United States and less than 5 in 10,000 in Europe. The concept of orphan drugs emerged to address the challenges faced by patients with these conditions, including limited therapeutic options, lack of clinical data, and high development costs.

**Why the Correct Answer is Right:** Orphan drugs are the right answer because they are medications or treatments designed to address the specific needs of patients suffering from rare diseases. Unlike other drugs targeting common diseases with more patients, orphan drugs undergo a unique regulatory pathway to ensure they are safe and effective for the rare disease they are intended to treat. This pathway allows for faster approval and market exclusivity for the drug manufacturer.

**Why Each Wrong Option is Incorrect:**

A. Unique drugs are not specific to rare diseases and could encompass a broader range of medications targeting common conditions.
B. Niche drugs are drugs targeting a small market, but the term "niche" does not accurately describe the specific purpose of orphan drugs for rare diseases.
C. Exclusive drugs are drugs that receive market exclusivity in the market, but this term is not specific to drugs targeting rare diseases.

**Why Orphan Drugs are Crucial:** Orphan drugs are essential as they cater to the specific needs of patients with rare diseases. By focusing on these conditions, they can address unmet medical needs, provide better management options, and improve the quality of life for patients with rare diseases. Additionally, these drugs contribute to the scientific understanding of these diseases, leading to further research and development of therapies.

**Clinical Pearl:** Orphan drug development can be facilitated by creating a conducive environment for pharmaceutical companies, including regulatory incentives like accelerated approval and market exclusivity. This encourages companies to invest in the development of treatments for rare diseases, benefiting patients and advancing medical knowledge.

**Example of Orphan Drugs:** An example of an orphan drug is Eculizumab, a monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Eculizumab is a significant example as it has significantly improved the prognosis and quality of life for patients with PNH. This case highlights the importance of orphan drug development, which can lead to significant medical advancements and improved patient outcomes.